Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001
Source: European Journal of Paediatric Neurology - Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
More News: Avonex | Brain | France Health | Gilenya | Multiple Sclerosis | Neurology | Pediatrics | Rebif | Study | Tysabri